109 filings
Page 4 of 6
8-K
4x5osw3jzac8o067plf
13 Jan 22
Results of Operations and Financial Condition
8:50am
8-K
8z8qd
21 Dec 21
Departure of Directors or Certain Officers
4:05pm
8-K
jj1vzpd2vmy
15 Nov 21
Landos Biopharma Reports Third Quarter 2021 Financial Results and Provides Corporate Update
8:27am
8-K
14307kirca9gu2ytp
10 Nov 21
Departure of Directors or Certain Officers
4:49pm
8-K
ad7skaa jk2vtw74zntq
3 Nov 21
Landos Biopharma Announces FDA Clearance of its IND for LABP-104 for the Treatment of Rheumatoid Arthritis
8:00am
8-K
5o7c33f
28 Oct 21
Landos Biopharma Announces First Subject Dosed in a Phase 1 Study of LABP-104 for Systemic Lupus Erythematosus
4:01pm
8-K
dn70qwwej43
12 Oct 21
Landos Biopharma Announces FDA Clearance of its IND for LABP-104 for the Treatment of Systemic Lupus Erythematosus
8:05am
8-K
2y2po
8 Oct 21
Regulation FD Disclosure
8:00am
8-K
hgzfe 2gu55ncjkarm
22 Sep 21
Regulation FD Disclosure
8:00am
8-K
ptr0gbcohexrudh71a4
17 Sep 21
Landos Biopharma to Present Results of LABP-104 in Lupus at the American College of
6:40am
8-K
00r21ixz aui0jg
27 Aug 21
Departure of Directors or Certain Officers
5:20pm
8-K
niyqb4 iar8
26 Aug 21
Landos Biopharma Announces Research Collaboration into the NLRX1 Pathway in Multiple Sclerosis with Johns Hopkins University School of Medicine
8:01am
8-K
60pjce
2 Aug 21
Landos Biopharma Reports Second Quarter 2021 Financial Results and Provides Business Updates
4:02pm
8-K
2kf3mzvcwcsu 77mn9f
22 Jul 21
Landos Biopharma’s Phase 2 Data of Omilancor in Ulcerative Colitis Accepted for Oral Presentation at the United European Gastroenterology Week 2021
8:06am
8-K
aq3k7rq yofomp249a3
14 Jun 21
Regulation FD Disclosure
5:09pm
8-K
2o30vf
19 May 21
Landos Biopharma Announces the Appointment of Tim M. Mayleben to its Board of Directors
8:52am
8-K
fqw1eikdgk9z 6rrucg
17 May 21
Landos Biopharma Reports First Quarter 2021 Financial Results and Provides Business Updates
9:23am
S-8
8iqs0t
17 May 21
Registration of securities for employees
9:17am